Official title and information are available only for Plus and Premium subscribers.
Technology A novel method for predicting patient response to neo-adjuvant chemoradiotherapy using label-free spectroscopic imaging. The technology uses biomarkers to predict response rates in a patient group, which typically has a responder rate of only 20%, in a high-cost treatment area. Proof of concept work has begun, and the technology will be further developed into a predicative software.
To see the additional information details please login and subscribe to a Plus or Premium account.
